Difference between revisions of "ICRP Glossary"
Jump to navigation
Jump to search
(→M) |
|||
(35 intermediate revisions by the same user not shown) | |||
Line 8: | Line 8: | ||
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary. | Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary. | ||
− | Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications. | + | Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in [[ICRP publications]]. |
---- | ---- | ||
Line 131: | Line 131: | ||
*[[Autoimmune disease]] | *[[Autoimmune disease]] | ||
+ | |||
+ | *[[Automatic exposure control]] | ||
*[[Autonomy]] | *[[Autonomy]] | ||
Line 248: | Line 250: | ||
*[[Collective dose]] | *[[Collective dose]] | ||
− | *[[Collective effective dose]] | + | *[[Collective effective dose]] |
*[[Collimation]] | *[[Collimation]] | ||
Line 294: | Line 296: | ||
*[[Cross section]] | *[[Cross section]] | ||
− | *[[ | + | *Cumulative air kerma (see [[Air kerma at the patient entrance reference point]]) |
*[[Cumulative dose]] | *[[Cumulative dose]] | ||
Line 325: | Line 327: | ||
*[[Decontamination factor]] | *[[Decontamination factor]] | ||
+ | |||
+ | *[[Dental and maxillofacial imaging]] | ||
*[[Deontological Ethics]] | *[[Deontological Ethics]] | ||
− | *[[Deposition]] | + | *[[Deposition]] (inhalation) |
*[[Derived air concentration]] | *[[Derived air concentration]] | ||
Line 398: | Line 402: | ||
*[[Dose criteria]] | *[[Dose criteria]] | ||
− | *[[Dose | + | *[[Dose equivalent]] in an organ or tissue |
− | *[[Dose | + | *[[Dose limit]] |
− | *[[Dose | + | *[[Dose modifying factor]] |
− | *[[Dose | + | *[[Dose of record (E)]] |
− | *[[Dose | + | *[[Dose of record Hp (10)]] |
*[[Dose per content function]] | *[[Dose per content function]] | ||
Line 615: | Line 619: | ||
*[[Ground-level enhancement]] | *[[Ground-level enhancement]] | ||
+ | |||
+ | *[[Growth factor]] | ||
*[[Growth fraction]] | *[[Growth fraction]] | ||
Line 628: | Line 634: | ||
*[[Half-life, physical]] | *[[Half-life, physical]] | ||
− | *HATM (see [[Human Alimentary Tract Model]] | + | *HATM (see [[Human Alimentary Tract Model]]) |
*[[Hazard]] | *[[Hazard]] | ||
Line 649: | Line 655: | ||
*[[Hounsfield unit]] | *[[Hounsfield unit]] | ||
+ | |||
+ | *HRTM (see [[Human Respiratory Tract Model]]) | ||
*[[Human Alimentary Tract Model]] | *[[Human Alimentary Tract Model]] | ||
− | *[[Human | + | *[[Human Respiratory Tract Model]] |
*[[Hyperbaric oxygen]] | *[[Hyperbaric oxygen]] | ||
Line 739: | Line 747: | ||
=== <big><span id="L">L</span></big> === | === <big><span id="L">L</span></big> === | ||
+ | |||
+ | *[[Lag]] | ||
*[[Late normal tissue responses]] | *[[Late normal tissue responses]] | ||
Line 850: | Line 860: | ||
*NHEJ (see [[Non-homologous end joining]]) | *NHEJ (see [[Non-homologous end joining]]) | ||
− | *[[Noise]] | + | *[[Noise]] (in imaging) |
*[[Nominal value]] | *[[Nominal value]] | ||
*[[Nominal risk coefficient]] | *[[Nominal risk coefficient]] | ||
− | |||
− | |||
*[[Non-homologous end joining]] | *[[Non-homologous end joining]] | ||
Line 868: | Line 876: | ||
*[[Normal tissue complication probability]] | *[[Normal tissue complication probability]] | ||
− | *[[Notification value]] | + | *[[Notification value]] (in CT) |
*[[Nuclear medicine]] | *[[Nuclear medicine]] | ||
Line 890: | Line 898: | ||
*[[Operating management]] | *[[Operating management]] | ||
− | *[[Operational | + | *[[Operational quantity]] |
*[[Optimisation]] | *[[Optimisation]] | ||
Line 896: | Line 904: | ||
*[[Optimisation of protection]] | *[[Optimisation of protection]] | ||
− | * | + | *Organ absorbed dose (see [[Organ/tissue absorbed dose]]) |
*[[Organ at risk]] | *[[Organ at risk]] | ||
Line 916: | Line 924: | ||
*Particle fluence (see [[Fluence]]) | *Particle fluence (see [[Fluence]]) | ||
− | *[[Particle transport]] | + | *[[Particle transport]] (in biokinetics) |
*[[Particle radiance]] | *[[Particle radiance]] | ||
Line 953: | Line 961: | ||
*[[Potential exposure]] | *[[Potential exposure]] | ||
+ | |||
+ | *[[Potential recoverability correction factor]] | ||
*[[Potentially lethal damage repair]] | *[[Potentially lethal damage repair]] | ||
Line 959: | Line 969: | ||
*[[Practice]] | *[[Practice]] | ||
+ | |||
+ | *PRCF (see [[Potential recoverability correction factor]]) | ||
*[[Prevailing circumstances]] | *[[Prevailing circumstances]] | ||
Line 994: | Line 1,006: | ||
*[[Qualified expert]] | *[[Qualified expert]] | ||
− | *[[Quality control testing]] | + | *[[Quality control testing]] (x-ray equipment) |
*[[Quality factor]], Q(L) | *[[Quality factor]], Q(L) | ||
Line 1,017: | Line 1,029: | ||
*[[Radiation-induced second cancer]] | *[[Radiation-induced second cancer]] | ||
+ | |||
+ | *[[Radiation-induced secondary malignancy]] | ||
*[[Radiation worker]] | *[[Radiation worker]] | ||
Line 1,082: | Line 1,096: | ||
*[[Referrer]] | *[[Referrer]] | ||
− | *Reference female (see [[Reference | + | *Reference female (see [[Reference Person]]) |
*[[Reference individual]] | *[[Reference individual]] | ||
Line 1,088: | Line 1,102: | ||
*[[Reference level]] | *[[Reference level]] | ||
− | *Reference male (see [[Reference | + | *Reference male (see [[Reference Person]]) |
*[[Reference parameter value]] | *[[Reference parameter value]] | ||
Line 1,157: | Line 1,171: | ||
*[[Risk model]] | *[[Risk model]] | ||
+ | |||
+ | *RISM (see [[Radiation-induced secondary malignancy]]) | ||
*Risk of exposure-induced death (see (see [[Lifetime risk estimates]]) | *Risk of exposure-induced death (see (see [[Lifetime risk estimates]]) | ||
Line 1,168: | Line 1,184: | ||
=== <big><span id="S">S</span></big> === | === <big><span id="S">S</span></big> === | ||
− | *[[S coefficient (radiation weighted)] | + | *[[S coefficient (radiation weighted)]] |
− | * SAF (see [[Specific absorbed fraction]]) | + | *SAF (see [[Specific absorbed fraction]]) |
*[[Safety case]] | *[[Safety case]] | ||
Line 1,183: | Line 1,199: | ||
*[[Secondary radiation]] | *[[Secondary radiation]] | ||
+ | |||
+ | *[[Secretory cells]] | ||
*[[Security]] | *[[Security]] | ||
Line 1,294: | Line 1,312: | ||
*[[Threshold dose for tissue reactions]] | *[[Threshold dose for tissue reactions]] | ||
− | *[[Threshold | + | *[[Threshold level]] |
− | * | + | *Tissue absorbed dose (see [[Organ/tissue absorbed dose]]) |
*[[Thoron progeny]] | *[[Thoron progeny]] | ||
Line 1,314: | Line 1,332: | ||
*[[Tolerability]] | *[[Tolerability]] | ||
− | *[[Tolerance dose]] | + | *[[Tolerance dose]] (in Radiotherapy) |
*[[Track structure]] | *[[Track structure]] | ||
Line 1,346: | Line 1,364: | ||
*[[Types of materials]] | *[[Types of materials]] | ||
− | *[[Typical value]] | + | *[[Typical value]] (for DRL) |
=== <big><span id="U">U</span></big> === | === <big><span id="U">U</span></big> === |
Latest revision as of 14:37, 3 October 2021
The ICRP Glossary collects ICRP’s definitive explanations of terms for current use. Some entries include historical descriptions to help readers better understand the term in a particular context.
It is a living document, updated regularly.
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
0-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ... |
0-9
- 4DCT (see Time-resolved computed tomography)
A
- Acute radiation sickness (see Acute radiation syndrome)
- ALI (see Annual limit on intake)
- AMAD (see Activity median aerodynamic diameter)
- Ambient dose equivalent, H*(10)
- ARS (see Acute radiation syndrome)
B
- BAT (see Best available techniques)
- Bcr/abl (see Breakpoint cluster region/abelson)
C
- CACA (see Cobblestone area forming cell assay)
- CAFC (see Cobblestone area forming cell assay)
- CBCT (see Cone beam computed tomography)
- Cobblestone area cell assay (see Cobblestone area forming cell assay)
- CR (see Concentration ratio)
- Cumulative air kerma (see Air kerma at the patient entrance reference point)
D
- DAC (see Derived air concentration)
- DBT (see Digital breast tomosynthesis)
- DCRL (see Derived consideration reference level)
- DD (see Doubling dose)
- DDI, detector dose indicator (see Exposure index)
- DIL (see Derived investigation level)
- DDREF (see Dose and dose-rate effectiveness factor)
- Deposition (inhalation)
- Detector dose indicator (see Exposure index)
- Directional dose equivalent H’(d,Ω)
- DLP (see Dose-length product)
- Dose (of ionising radiation)
- Dose equivalent in an organ or tissue
- DQE (see Detector quantum efficiency)
- DRL (see Diagnostic reference level)
E
- EAR (see Excess absolute risk)
- EI (see Exposure index)
- ELR (i.e. Excess Lifetime Risk, see Lifetime risk estimates)
- Endosteal tissue (see Endosteum)
- ERR (see Excess relative risk)
- Excess lifetime risk (see Lifetime risk estimates)
F
- Fluence, Φ
- FSU (see Functional subunits)
G
- GATA-2 (see GATA binding protein 2)
- Geomagnetic cut-off rigidity (see Rigidity threshold)
- Gray (Gy)
H
- HATM (see Human Alimentary Tract Model)
- HRTM (see Human Respiratory Tract Model)
I
- IMRT (see Intensity-modulated radiotherapy)
- Incidence rate (see Incidence)
J
K
- Kerma, K
L
- LET (see Linear energy transfer)
- LLE (see Lifetime risk estimates)
- Loss of Life Expectancy (see Lifetime risk estimates)
- LSS (see Life Span Study)
M
- MDCT (see Multi-detector computed tomography)
- MMD (see Mass median diameter)
N
- NHEJ (see Non-homologous end joining)
- Noise (in imaging)
- Notification value (in CT)
O
- OAR (see Organ at risk)
- OEA (see Oxygen enhancement ratio)
- Organ absorbed dose (see Organ/tissue absorbed dose)
P
- Particle fluence (see Fluence)
- Particle transport (in biokinetics)
- Personal dose equivalent, Hp(d)
- PLDR (see Potentially lethal damage repair)
- PRCF (see Potential recoverability correction factor)
Q
- Quality control testing (x-ray equipment)
- Quality factor, Q(L)
R
- Radiation detriment (see Detriment)
- RAP (see Reference Animal and Plant)
- RBE (see Relative biological effectiveness)
- Reference female (see Reference Person)
- Reference male (see Reference Person)
- REID (see Lifetime risk estimates)
- Response function (see Dose-response function)
- RISM (see Radiation-induced secondary malignancy)
- Risk of exposure-induced death (see (see Lifetime risk estimates)
- ROS (see Reactive oxygen species)
- RR (see Relative risk)
S
- SAF (see Specific absorbed fraction)
- SEE (see Specific effective energy]
- Sievert (Sv)
- SLDR (see Sublethal damage repair)
- Slice (in CT & CBCT)
- SOBP (see Spread-out Bragg peak)
- Source (see Radiation source)
- Superposition principle (in dosimetry)
T
- Tissue absorbed dose (see Organ/tissue absorbed dose)
- Tolerance dose (in Radiotherapy)
- Transport of risk (see Transfer of risk)
- Typical value (for DRL)
U
V
W
- WL (see Working level)
- WLM (see Working level month)
- wT (see Tissue weighting factor)
- wR (see Radiation weighting factor)
X
Y
Z
...
- α/β ratio (see α/β value)